New generation antiplatelet therapies to prevent preeclampsia

预防先兆子痫的新一代抗血小板疗法

• 批准号: nhmrc : GNT1128093
• 负责人: Dr Natalie Hannan
• 金额: $ 48.31万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/new-generation-antiplatelet-prevent-preeclampsia/1347665
• 关键词: New; generation; antiplatelet; therapies; prevent

Preeclampsia, a major complication of pregnancy, affects around 3-8% of pregnancies. Sadly, there is no way to prevent or delay disease. We have uncovered antiplatelet agents, used to prevent heart disease and stroke, may provide health benefits to women at risk of developing preeclampsia. We will test whether these agents can prevent the pathophysiology of preeclampsia in specialized human & mouse models developed in our laboratory. This work may provide a prevention strategy for preeclampsia.

先兆子痫是妊娠的一个主要并发症，影响大约3%-8%的怀孕。可悲的是，没有办法预防或延缓疾病。我们发现了用于预防心脏病和中风的抗血小板药物，可能会为有先兆子痫风险的女性提供健康益处。我们将在我们实验室开发的专门的人和小鼠模型中测试这些药物是否可以预防先兆子痫的病理生理。这项工作可能为子痫前期的预防提供一种策略。